Huajian Medical has suspended its planned Ethereum acquisition, awaiting shareholder authorization in compliance with HKEX Chapter 14 disclosure obligations.
In an official announcement, Huajian Medical confirmed the suspension of its mid-August plan to acquire up to 3 billion yuan ($420 million) in cryptocurrency, specifically Ethereum. The Hong Kong-listed medical firm cited the need for additional time to secure shareholder approval. The company stated any future ETH purchases will be disclosed according to Hong Kong Exchanges and Clearing Limited (HKEX) Chapter 14 rules. This postponement is part of its broader strategic direction, which includes developing an artificial intelligence platform to enhance valuation model accuracy and improve asset securitization efficiency.